RxDoctor Payments Data

Emile Wassel, MD

Nephrology · Utica, NYNPI 1023047552

Payments from drug & device makers

$8,751in general payments, 2019–2025

Across 398 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Bayer$1K
  • AstraZeneca$1K
  • Otsuka America Pharmaceutical, Inc.$489
  • Calliditas Therapeutics US Inc.$450
  • Harmony Biosciences LLC$440
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$220%
  • Food & beverage$8,36796%
  • Education$3624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,751 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$442,130
Medicare patients
874
Services billed
4,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone233$231,984
FarxigaDapagliflozin Propanediol194$190,037
JardianceEmpagliflozin169$170,448
XphozahTenapanor Hcl51$158,728
JanuviaSitagliptin Phosphate44$39,869
LokelmaSodium Zirconium Cyclosilicate51$35,848
EliquisApixaban21$23,032
DapagliflozinDapagliflozin Propanediol40$19,680
Febuxostat71$14,502
Sevelamer Carbonate82$14,073
Allopurinol1,368$8,923
TradjentaLinagliptin15$8,633
Cinacalcet Hcl16$7,487
Torsemide277$5,467
Calcium Acetate59$4,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$1,180$231,984233 claims
AstraZenecaFarxiga, Lokelma$1,130$225,885245 claims
Boehringer IngelheimJardiance, Tradjenta$326$179,081184 claims
MerckJanuvia$16$39,86944 claims
PfizerEliquis$36$23,03221 claims
ANI Pharmaceuticals, Inc.Valsartan$110$57418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.

Other nephrology in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →